SKI 0 4TGNectria coccinea produces antibiotics LL-Z1272-p (1 b), -y (ascochlorin) (Za), -8 (3a). and -E (3b) together with a new metabolite for which the name chloronectrin and structure (3c) (based on 3-[5-(3-oxocyclohexyl)pent-2enyl]-5-chloro-orseliinaldehyde) are proposed. In the presence of bromide in place of chloride, N. coccinea produces an analogous 3-(penta-2,4-dienyl) -5-bromo-compound (2c). Several new derivatives in the series are reported.ANTIBIOTICS LL-21272 [a (la), p (1 b) , y (2a), 8 (3a), E (3b), and < (2b)l have been isolated from an unidentified Fusarium sp.l Antibiotic LL-21272 y (2a) (ascochlorin) published data it seems likely that ilicicolin A is identical with antibiotic LL-Z1272-a, B with -PI C with -6, D with -7, and F with -<, though no reference was made in ref. 4 to the work of Ellestad et a1.l We report here the isolation from Nectria coccinea of OR^ 0 R1 R2 R3 R4 a ; C1

It has been brought to our attention by Professor Ch. Tamm (University of Basel) that the name punctatin has been used previously1 for a group of homoisoflavanones isolated from Eucomis punctutu L'Herit. We therefore propose modifying the name of the fungal metabolites isolated from Poroniu punctutu described in the above two communications and related publications2J from punctatins to punctaporonins. Thus antibiotic M95464 becomes punctaporonin A, etc.

No abstract

No abstract

First described by Polish Neurologist Łucja Frey in 1923, Frey’s syndrome (FS), or auriculotemporal syndrome, is a rare condition characterised by gustatory sweating, typically encountered as sequelae following invasive head and neck surgery. The pathophysiology of FS can be described by aberrant reinnervation of postganglionic parasympathetic neurons to the surrounding denervated sweat glands and cutaneous blood vessels. Multiple invasive procedures have been associated with FS ranging from salivary gland surgery to burn reconstruction and thoracoscopic sympathectomies. Rarely, FS can be secondary to trauma or non-surgical aetiologies, including diabetes and infection. Physical symptoms vary based on the severity and surface area affected by FS and range from mild symptoms to severe psychosocial morbidity for patients. Surgeons operating in the head and neck, including otolaryngologists, maxillofacial surgeons, and plastic surgeons, should be aware of this potential complication and be up to date with diagnosis and treatment strategies for FS. This review article summarises the literature relating to FS focusing on its aetiologies, symptomatology, prevention, and available treatments, aiming to provide an up-to-date review of this condition for surgeons operating in the head and neck region. Although various treatment options have been suggested, these are often limited to topical agents that require life-long administration for symptom control. Further research is recommended to identify the optimal treatment for this condition and the role of surgery as a treatment for severe or refractory cases.